Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00479323 · ClinicalTrials.gov registry record · Phase 1
Pneumococcal Reference Standard
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT00479323 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 250 participants.
The verdict
NCT00479323, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low. The purpose of this study is to give the pneumococcal vaccine to healthy volunteers and take serum blood samples in order to increase the reference serum supply. Study participants will include 250 healthy men and women, ages 18-45. Study procedures will include a physical exam, interviews, blood samples and blood testing. All volunteers will receive the pneumococcal vaccine in the deltoid muscle of the arm. Participants will be involved in the study for approximately 17 weeks.
Interventions
- BIOLOGICAL Pneumovax 23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00479323
The ClinicalTrials.gov registry entry for NCT00479323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pneumovax 23 is the first listed.
NCT00479323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00479323 about?
NCT00479323 is a clinical study titled "Pneumococcal Reference Standard". Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low. The purpose of this study is to give the pneumococcal vaccine to healthy volunteers and take serum blood samples in order to i...
What is the current status of trial NCT00479323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2007-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00479323?
The interventions under investigation include: Pneumovax 23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00479323?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.